Neurenati Therapeutics, a Montreal, Canada-based biotech company developing therapies for rare diseases, raised $1.2M in Seed funding.
The round was led by Genson Capital.
The company intends to use the funds to accelerate the development of NEU-001, a therapy to Hirschsprung’s disease (HSCR), a rare gastrointestinal condition affecting approximately 100 Canadian newborns every year.
Led by Maxime Ranger, President and CEO, Neurenati Therapeutics is a biotech company dedicated to developing therapies for rare diseases. The first technology targets Hirschsprung disease (HSCR), a life-threatening gastrointestinal (GI) birth defect characterized by the lack of nerves in parts of the lower GI tract. It proposes a therapy via growth factor to treat newborns with HSCR, thereby averting the need for surgery and its associated complications.
Neurenati Therapeutics also announced the appointment of Alexandre Lebeaut as independent director of the Board.
FinSMEs
29/02/2024